Proteins > E3 ubiquitin-protein ligase Mdm2
Page last updated: 2024-08-07 16:57:52
E3 ubiquitin-protein ligase Mdm2
An E3 ubiquitin-protein ligase Mdm2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00987]
Synonyms
EC 2.3.2.27;
Double minute 2 protein;
Hdm2;
Oncoprotein Mdm2;
RING-type E3 ubiquitin transferase Mdm2;
p53-binding protein Mdm2
Research
Bioassay Publications (70)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (11.43) | 29.6817 |
2010's | 53 (75.71) | 24.3611 |
2020's | 9 (12.86) | 2.80 |
Compounds (19)
Drugs with Potency Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
nutlin 2 | Homo sapiens (human) | Potency | 0.3000 | 1 | 1 |
nutlin-3a | Homo sapiens (human) | Potency | 0.3000 | 1 | 1 |
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
catechol | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
gossypol | Homo sapiens (human) | Ki | 25.0000 | 1 | 1 |
quinone | Homo sapiens (human) | IC50 | 13.9000 | 1 | 1 |
vorinostat | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
apomorphine | Homo sapiens (human) | IC50 | 10.1367 | 3 | 3 |
cytarabine | Homo sapiens (human) | IC50 | 0.0200 | 1 | 1 |
nutlin 3 | Homo sapiens (human) | IC50 | 0.2948 | 3 | 3 |
nutlin 3 | Homo sapiens (human) | Ki | 0.0955 | 4 | 4 |
nutlin 2 | Homo sapiens (human) | IC50 | 0.1400 | 4 | 4 |
nutlin 1 | Homo sapiens (human) | IC50 | 1.7133 | 3 | 3 |
nutlin 1 | Homo sapiens (human) | Ki | 1.2400 | 1 | 1 |
nutlin-3a | Homo sapiens (human) | IC50 | 1.4548 | 34 | 34 |
nutlin-3a | Homo sapiens (human) | Ki | 0.0860 | 15 | 15 |
MI-63 | Homo sapiens (human) | IC50 | 3.6677 | 5 | 5 |
MI-63 | Homo sapiens (human) | Ki | 0.0027 | 4 | 4 |
nutlin-3b | Homo sapiens (human) | IC50 | 6.8540 | 2 | 2 |
nutlin-3b | Homo sapiens (human) | Ki | 0.1984 | 1 | 1 |
pb 12 | Homo sapiens (human) | Ki | 0.9176 | 5 | 5 |
spautin-1 | Homo sapiens (human) | IC50 | 0.6000 | 1 | 1 |
nvp-cgm097 | Homo sapiens (human) | IC50 | 2.5568 | 4 | 4 |
nvp-cgm097 | Homo sapiens (human) | Ki | 0.0013 | 1 | 1 |
rg7388 | Homo sapiens (human) | IC50 | 0.0078 | 4 | 4 |
sar405838 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 1 |
sar405838 | Homo sapiens (human) | Ki | 0.0020 | 8 | 8 |
rg7112 | Homo sapiens (human) | IC50 | 0.0180 | 4 | 4 |
amg 232 | Homo sapiens (human) | IC50 | 0.0006 | 4 | 4 |
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
nutlin 3 | Homo sapiens (human) | Kd | 0.2400 | 1 | 1 |
nutlin-3a | Homo sapiens (human) | Kd | 0.6050 | 7 | 7 |
nutlin-3b | Homo sapiens (human) | Kd | 0.1500 | 1 | 1 |
nvp-cgm097 | Homo sapiens (human) | Kd | 0.0023 | 1 | 1 |
rg7388 | Homo sapiens (human) | Kd | 0.0050 | 2 | 2 |
sar405838 | Homo sapiens (human) | Kd | 0.0027 | 1 | 1 |
rg7112 | Homo sapiens (human) | Kd | 0.0068 | 2 | 2 |
amg 232 | Homo sapiens (human) | Kd | 0.0000 | 3 | 3 |
Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation.European journal of medicinal chemistry, , May-05, Volume: 217, 2021
α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.Journal of medicinal chemistry, , 02-13, Volume: 63, Issue:3, 2020
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.Journal of medicinal chemistry, , 05-26, Volume: 59, Issue:10, 2016
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 22, Issue:20, 2012
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.Journal of medicinal chemistry, , Jun-29, Volume: 49, Issue:13, 2006
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.Bioorganic & medicinal chemistry, , Jul-15, Volume: 21, Issue:14, 2013
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 22, Issue:20, 2012
The p53-MDM2/MDMX axis - A chemotype perspective.MedChemComm, , Volume: 2, 2011
p53 Activation by small molecules: application in oncology.Journal of medicinal chemistry, , Jul-14, Volume: 48, Issue:14, 2005
Role of p53 circuitry in tumorigenesis: A brief review.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.Bioorganic & medicinal chemistry letters, , May-01, Volume: 23, Issue:9, 2013
Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors.Bioorganic & medicinal chemistry, , Feb-15, Volume: 20, Issue:4, 2012
Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.Bioorganic & medicinal chemistry, , Sep-15, Volume: 19, Issue:18, 2011
[no title available]Journal of medicinal chemistry, , 04-28, Volume: 65, Issue:8, 2022
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.European journal of medicinal chemistry, , Jun-05, Volume: 236, 2022
A critical update on the strategies towards modulators targeting androgen receptors.Bioorganic & medicinal chemistry, , 07-01, Volume: 28, Issue:13, 2020
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.Journal of medicinal chemistry, , 08-13, Volume: 63, Issue:15, 2020
HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.ACS medicinal chemistry letters, , May-14, Volume: 11, Issue:5, 2020
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Role of p53 circuitry in tumorigenesis: A brief review.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.Journal of medicinal chemistry, , 10-25, Volume: 61, Issue:20, 2018
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.Journal of medicinal chemistry, , 08-23, Volume: 61, Issue:16, 2018
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.Bioorganic & medicinal chemistry letters, , 11-01, Volume: 28, Issue:20, 2018
Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonistsMedChemComm, , May-01, Volume: 8, Issue:5, 2017
Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.Bioorganic & medicinal chemistry, , Apr-15, Volume: 24, Issue:8, 2016
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.Bioorganic & medicinal chemistry letters, , 10-01, Volume: 26, Issue:19, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.ACS medicinal chemistry letters, , Mar-10, Volume: 7, Issue:3, 2016
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 25, Issue:17, 2015
Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 25, Issue:21, 2015
Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.European journal of medicinal chemistry, , Jun-23, Volume: 81, 2014
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 24, Issue:8, 2014
Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 24, Issue:12, 2014
Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.Bioorganic & medicinal chemistry, , Apr-15, Volume: 21, Issue:8, 2013
Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 23, Issue:3, 2013
Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.ACS medicinal chemistry letters, , May-09, Volume: 4, Issue:5, 2013
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.Bioorganic & medicinal chemistry letters, , May-01, Volume: 23, Issue:9, 2013
Rational design and binding mode duality of MDM2-p53 inhibitors.Journal of medicinal chemistry, , May-23, Volume: 56, Issue:10, 2013
Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Chemical modulators working at pharmacological interface of target proteins.Bioorganic & medicinal chemistry, , Mar-15, Volume: 20, Issue:6, 2012
Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.European journal of medicinal chemistry, , Volume: 56, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Jun-14, Volume: 55, Issue:11, 2012
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 22, Issue:20, 2012
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.Bioorganic & medicinal chemistry letters, , May-15, Volume: 22, Issue:10, 2012
Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.European journal of medicinal chemistry, , Volume: 46, Issue:11, 2011
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.Journal of medicinal chemistry, , Mar-10, Volume: 54, Issue:5, 2011
Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 21, Issue:5, 2011
N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.Bioorganic & medicinal chemistry, , Dec-01, Volume: 17, Issue:23, 2009
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 18, Issue:22, 2008
NMR screening for lead compounds using tryptophan-mutated proteins.Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.Nature, , Dec-13, Volume: 450, Issue:7172, 2007
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.Journal of medicinal chemistry, , Jun-29, Volume: 49, Issue:13, 2006
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006
p53 Activation by small molecules: application in oncology.Journal of medicinal chemistry, , Jul-14, Volume: 48, Issue:14, 2005
Structure-based design of novel inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Jun-14, Volume: 55, Issue:11, 2012
The p53-MDM2/MDMX axis - A chemotype perspective.MedChemComm, , Volume: 2, 2011
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Dec-24, Volume: 52, Issue:24, 2009
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006
Design, synthesis and biological evaluation of novel antitumor spirodihydrothiopyran-oxindole derivatives.Bioorganic & medicinal chemistry letters, , 07-01, Volume: 29, Issue:13, 2019
Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017
Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity.Journal of medicinal chemistry, , 10-12, Volume: 60, Issue:19, 2017
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 22, Issue:20, 2012
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 25, Issue:24, 2015
Hot spot-based design of small-molecule inhibitors for protein-protein interactions.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 24, Issue:11, 2014
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.Bioorganic & medicinal chemistry, , Jul-15, Volume: 21, Issue:14, 2013
The p53-MDM2/MDMX axis - A chemotype perspective.MedChemComm, , Volume: 2, 2011
[no title available]Journal of medicinal chemistry, , 04-28, Volume: 65, Issue:8, 2022
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Discovery of Journal of medicinal chemistry, , 11-11, Volume: 64, Issue:21, 2021
Development of selective small molecule MDM2 degraders based on nutlin.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.Bioorganic & medicinal chemistry, , Aug-01, Volume: 22, Issue:15, 2014
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.Journal of medicinal chemistry, , Feb-27, Volume: 57, Issue:4, 2014
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.Journal of medicinal chemistry, , Jul-25, Volume: 56, Issue:14, 2013
Discovery of Journal of medicinal chemistry, , 11-11, Volume: 64, Issue:21, 2021
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.Journal of medicinal chemistry, , 11-25, Volume: 63, Issue:22, 2020
Development of selective small molecule MDM2 degraders based on nutlin.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.European journal of medicinal chemistry, , Nov-05, Volume: 159, 2018
Role of p53 circuitry in tumorigenesis: A brief review.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.Journal of medicinal chemistry, , Feb-27, Volume: 57, Issue:4, 2014
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.Bioorganic & medicinal chemistry letters, , May-01, Volume: 23, Issue:9, 2013
[no title available]Journal of medicinal chemistry, , 04-28, Volume: 65, Issue:8, 2022
Discovery of Journal of medicinal chemistry, , 11-11, Volume: 64, Issue:21, 2021
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.Journal of medicinal chemistry, , 08-13, Volume: 63, Issue:15, 2020
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.Journal of medicinal chemistry, , Feb-27, Volume: 57, Issue:4, 2014
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.Journal of medicinal chemistry, , Jul-25, Volume: 56, Issue:14, 2013
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.ACS medicinal chemistry letters, , May-09, Volume: 4, Issue:5, 2013
[no title available]Journal of medicinal chemistry, , 04-28, Volume: 65, Issue:8, 2022
Development of selective small molecule MDM2 degraders based on nutlin.European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.Journal of medicinal chemistry, , Dec-26, Volume: 57, Issue:24, 2014
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.Journal of medicinal chemistry, , Feb-27, Volume: 57, Issue:4, 2014
Enables
This protein enables 18 target(s):
Target | Category | Definition |
p53 binding | molecular function | Binding to one of the p53 family of proteins. [GOC:hjd] |
ubiquitin-protein transferase activity | molecular function | Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y = Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages. [GOC:BioGRID, GOC:jh2, PMID:9635407] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
5S rRNA binding | molecular function | Binding to a 5S ribosomal RNA, the smallest RNA constituent of a ribosome. [GOC:jl, ISBN:0321000382] |
zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
ligase activity | molecular function | Catalysis of the joining of two molecules, or two groups within a single molecule, using the energy from the hydrolysis of ATP, a similar triphosphate, or a pH gradient. [GOC:mah] |
SUMO transferase activity | molecular function | Catalysis of the transfer of SUMO from one protein to another via the reaction X-SUMO + Y = Y-SUMO + X, where both X-SUMO and Y-SUMO are covalent linkages. [GOC:rn, PMID:11031248, PMID:11265250] |
enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
protein domain specific binding | molecular function | Binding to a specific domain of a protein. [GOC:go_curators] |
ubiquitin protein ligase binding | molecular function | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. [GOC:vp] |
receptor serine/threonine kinase binding | molecular function | Binding to a receptor that possesses protein serine/threonine kinase activity. [GOC:mah] |
identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
peroxisome proliferator activated receptor binding | molecular function | Binding to a peroxisome proliferator activated receptor, alpha, beta or gamma. [GOC:jl, PMID:12769781] |
ribonucleoprotein complex binding | molecular function | Binding to a complex of RNA and protein. [GOC:bf, GOC:go_curators, GOC:vk] |
ubiquitin binding | molecular function | Binding to ubiquitin, a protein that when covalently bound to other cellular proteins marks them for proteolytic degradation. [GOC:ecd] |
ubiquitin protein ligase activity | molecular function | Catalysis of the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S = X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues. [GOC:BioGRID, GOC:dph, GOC:mah, GOC:tb, PMID:22863777] |
NEDD8 ligase activity | molecular function | Catalysis of the transfer of NEDD8 to a substrate protein via the reaction X-NEDD8 + S = X + S-NEDD8, where X is either an E2 or E3 enzyme, the X-NEDD8 linkage is a thioester bond, and the S-NEDD8 linkage is an isopeptide bond between the C-terminal amino acid of NEDD8 and the epsilon-amino group of lysine residues in the substrate. [GOC:dph] |
disordered domain specific binding | molecular function | Binding to a disordered domain of a protein. [GOC:gg, PMID:11746698] |
Located In
This protein is located in 7 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
nucleolus | cellular component | A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome. [ISBN:0198506732] |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
endocytic vesicle membrane | cellular component | The lipid bilayer surrounding an endocytic vesicle. [GOC:mah] |
Part Of
This protein is part of 2 target(s):
Target | Category | Definition |
transcription repressor complex | cellular component | A protein complex that possesses activity that prevents or downregulates transcription. [GOC:mah] |
protein-containing complex | cellular component | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. [GOC:dos, GOC:mah] |
Involved In
This protein is involved in 63 target(s):
Target | Category | Definition |
negative regulation of transcription by RNA polymerase II | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. [GOC:go_curators, GOC:txnOH] |
protein polyubiquitination | biological process | Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain. [ISBN:0815316194] |
blood vessel development | biological process | The process whose specific outcome is the progression of a blood vessel over time, from its formation to the mature structure. The blood vessel is the vasculature carrying blood. [GOC:hjd, UBERON:0001981] |
blood vessel remodeling | biological process | The reorganization or renovation of existing blood vessels. [GOC:hjd] |
regulation of heart rate | biological process | Any process that modulates the frequency or rate of heart contraction. [GOC:dph, GOC:tb, PMID:10358008] |
atrioventricular valve morphogenesis | biological process | The process in which the structure of the atrioventricular valve is generated and organized. [GOC:mtg_heart] |
endocardial cushion morphogenesis | biological process | The process in which the anatomical structure of the endocardial cushion is generated and organized. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves. [GOC:mtg_heart] |
ventricular septum development | biological process | The progression of the ventricular septum over time from its formation to the mature structure. [GOC:mtg_heart] |
atrial septum development | biological process | The progression of the atrial septum over time, from its initial formation to the mature structure. [GOC:mtg_heart] |
ubiquitin-dependent protein catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein. [GOC:go_curators] |
apoptotic process | biological process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263] |
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | biological process | A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage and resulting in the stopping or reduction in rate of the cell cycle. [GOC:go_curators] |
traversing start control point of mitotic cell cycle | biological process | A cell cycle process by which a cell commits to entering S phase via a positive feedback mechanism between the regulation of transcription and G1 CDK activity. [GOC:mtg_cell_cycle] |
positive regulation of cell population proliferation | biological process | Any process that activates or increases the rate or extent of cell proliferation. [GOC:go_curators] |
response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
response to toxic substance | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus. [GOC:lr] |
response to iron ion | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus. [GOC:sm] |
positive regulation of gene expression | biological process | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
negative regulation of protein processing | biological process | Any process that decreases the rate, frequency or extent of protein maturation by peptide bond cleavage. [GOC:dph, GOC:mah, GOC:tb] |
negative regulation of neuron projection development | biological process | Any process that decreases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). [GOC:dph, GOC:tb] |
protein ubiquitination | biological process | The process in which one or more ubiquitin groups are added to a protein. [GOC:ai] |
protein sumoylation | biological process | The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxy-terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein. [GOC:jl, PMID:11265250] |
protein destabilization | biological process | Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation. [GOC:mah] |
response to magnesium ion | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnesium ion stimulus. [GOC:mah] |
positive regulation of proteasomal ubiquitin-dependent protein catabolic process | biological process | Any process that activates or increases the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. [GOC:mah] |
protein localization to nucleus | biological process | A process in which a protein transports or maintains the localization of another protein to the nucleus. [GOC:ecd] |
regulation of protein catabolic process | biological process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. [GOC:go_curators, GOC:jl] |
response to cocaine | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant. [GOC:ef, GOC:jl] |
proteasome-mediated ubiquitin-dependent protein catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. [GOC:go_curators] |
negative regulation of DNA damage response, signal transduction by p53 class mediator | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage. [GOC:jl] |
establishment of protein localization | biological process | The directed movement of a protein to a specific location. [GOC:bf] |
response to ether | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ether stimulus. [GOC:go_curators] |
negative regulation of DNA-templated transcription | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. [GOC:go_curators, GOC:txnOH] |
positive regulation of mitotic cell cycle | biological process | Any process that activates or increases the rate or extent of progression through the mitotic cell cycle. [GOC:dph, GOC:go_curators, GOC:tb] |
response to antibiotic | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antibiotic stimulus. An antibiotic is a chemical substance produced by a microorganism which has the capacity to inhibit the growth of or to kill other microorganisms. [GOC:ai, GOC:ef] |
positive regulation of protein export from nucleus | biological process | Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm. [GOC:bf] |
response to steroid hormone | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a steroid hormone stimulus. [GOC:go_curators] |
positive regulation of muscle cell differentiation | biological process | Any process that activates or increases the frequency, rate or extent of muscle cell differentiation. [CL:0000187, GOC:ai] |
proteolysis involved in protein catabolic process | biological process | The hydrolysis of a peptide bond or bonds within a protein as part of the chemical reactions and pathways resulting in the breakdown of a protein by individual cells. [GOC:ai, GOC:dph, GOC:tb] |
protein autoubiquitination | biological process | The ubiquitination by a protein of one or more of its own amino acid residues, or residues on an identical protein. Ubiquitination occurs on the lysine residue by formation of an isopeptide crosslink. [GOC:ai] |
cardiac septum morphogenesis | biological process | The process in which the anatomical structure of a cardiac septum is generated and organized. A cardiac septum is a partition that separates parts of the heart. [GOC:dph, GOC:mtg_heart] |
protein-containing complex assembly | biological process | The aggregation, arrangement and bonding together of a set of macromolecules to form a protein-containing complex. [GOC:jl] |
cellular response to hydrogen peroxide | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. [CHEBI:16240, GOC:mah] |
cellular response to vitamin B1 | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B1 stimulus. [GOC:mah] |
cellular response to alkaloid | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkaloid stimulus. Alkaloids are a large group of nitrogenous substances found in naturally in plants, many of which have extracts that are pharmacologically active. [GOC:mah] |
cellular response to growth factor stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus. [GOC:mah] |
cellular response to peptide hormone stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide hormone stimulus. A peptide hormone is any of a class of peptides that are secreted into the blood stream and have endocrine functions in living animals. [GOC:mah] |
cellular response to estrogen stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics. [GOC:mah] |
cellular response to hypoxia | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. [GOC:mah] |
cellular response to gamma radiation | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gamma radiation stimulus. Gamma radiation is a form of electromagnetic radiation (EMR) or light emission of a specific frequency produced from sub-atomic particle interaction, such as electron-positron annihilation and radioactive decay. Gamma rays are generally characterized as EMR having the highest frequency and energy, and also the shortest wavelength, within the electromagnetic radiation spectrum. [GOC:mah] |
cellular response to UV-C | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-C radiation stimulus. UV-C radiation (UV-C light) spans the wavelengths 100 to 280 nm. [GOC:mah] |
fibroblast activation | biological process | A change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand. [CL:0000057, GOC:BHF, GOC:mah] |
cellular response to actinomycin D | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an actinomycin D stimulus. [GOC:mah] |
negative regulation of signal transduction by p53 class mediator | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator. [GOC:TermGenie] |
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway by p53 class mediator. [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15705871] |
response to formaldehyde | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a formaldehyde stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:9149109] |
positive regulation of vascular associated smooth muscle cell proliferation | biological process | Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation. [GO_REF:0000058, GOC:TermGenie, PMID:23246467] |
positive regulation of vascular associated smooth muscle cell migration | biological process | Any process that activates or increases the frequency, rate or extent of vascular associated smooth muscle cell migration. [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20693317] |
amyloid fibril formation | biological process | The generation of amyloid fibrils, insoluble fibrous protein aggregates exhibiting beta sheet structure, from proteins. [GOC:cvs, GOC:jj, GOC:ppm, GOC:sj, PMID:21148556, PMID:22817896, PMID:28937655, PMID:29654159] |
response to water-immersion restraint stress | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of water immersion while being held immobile. [PMID:10882227] |
negative regulation of apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
cell cycle | biological process | The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. [GOC:go_curators, GOC:mtg_cell_cycle] |
regulation of gene expression | biological process | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |